{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:33:24Z","timestamp":1771666404862,"version":"3.50.1"},"reference-count":35,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1136\/bjophthalmol-2014-305189","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T04:03:41Z","timestamp":1406088221000},"page":"1642-1648","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy"],"prefix":"10.1136","volume":"98","author":[{"given":"Tsutomu","family":"Sakai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Ohkuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tsuneoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,7,22]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2014-305189-1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199001010-00001","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"10","author":"Yannuzzi","year":"1990","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305189-2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00006982-199515020-00003","article-title":"Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy","volume":"15","author":"Spaide","year":"1995","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305189-3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/archopht.1997.01100150480005","article-title":"The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy","volume":"115","author":"Yannuzzi","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.survophthal.2003.10.007","article-title":"Polypoidal choroidal vasculopathy","volume":"49","author":"Ciardella","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-5","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bjo.2003.032466","article-title":"Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy","volume":"88","author":"Matsuoka","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-7","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.ophtha.2006.12.021","article-title":"Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration","volume":"114","author":"Kikuchi","year":"2007","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305189-8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bjo.86.3.321","article-title":"Polypoidal choroidal vasculopathy treated with macular translocation: clinical pathological correlation","volume":"86","author":"Terasaki","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00417-012-2137-y","article-title":"Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy","volume":"251","author":"Nakata","year":"2013","journal-title":"Graefe Arch Clin Exp Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00006982-200210000-00001","article-title":"Treatment of polypoidal choroidal vasculopathy with photodynamic therapy","volume":"22","author":"Spaide","year":"2002","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305189-11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ophtha.2007.02.031","article-title":"One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients","volume":"115","author":"Gomi","year":"2008","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305189-12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/IAE.0b013e3181a3b7c5","article-title":"Two year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions","volume":"29","author":"Tsuchiya","year":"2009","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305189-13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ophtha.2007.10.018","article-title":"Guidelines for PDT in Japan","volume":"115","author":"Tano","year":"2008","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2014-305189-14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/IAE.0b013e31816577cb","article-title":"Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy","volume":"28","author":"Akaza","year":"2008","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305189-15","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/IAE.0b013e3181d37486","article-title":"Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3\u2005years of follow-up","volume":"30","author":"Leal","year":"2010","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305189-16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10384-010-0886-x","article-title":"Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy","volume":"55","author":"Akaza","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bjo.2007.135103","article-title":"Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy","volume":"92","author":"Lai","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-18","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ajo.2009.12.038","article-title":"Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy","volume":"149","author":"Sato","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ajo.2010.02.008","article-title":"Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy","volume":"150","author":"Gomi","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/jop.2009.0073","article-title":"Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy","volume":"26","author":"Lai","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"key-10.1136\/bjophthalmol-2014-305189-21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000323811","article-title":"Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy","volume":"225","author":"Moon","year":"2011","journal-title":"Ophthalmologica"},{"key":"key-10.1136\/bjophthalmol-2014-305189-22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000330793","article-title":"Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy","volume":"226","author":"Kim","year":"2011","journal-title":"Ophthalmologica"},{"key":"key-10.1136\/bjophthalmol-2014-305189-23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000330793","article-title":"Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy","volume":"226","author":"Kim","year":"2011","journal-title":"Ophthalmologica"},{"key":"key-10.1136\/bjophthalmol-2014-305189-24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ajo.2011.09.031","article-title":"Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy","volume":"153","author":"Sagong","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305189-26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ajo.2012.03.051","article-title":"Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up","volume":"154","author":"Lee","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10384-012-0206-8","article-title":"Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration","volume":"57","author":"Yoshizawa","year":"2013","journal-title":"Jpn J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-28","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ajo.2013.11.015","article-title":"Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome","volume":"157","author":"Kang","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-29","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","article-title":"Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy","volume":"156","author":"Kang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/bjophthalmol-2012-302652","article-title":"Results of 2\u2005years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy","volume":"97","author":"Hikichi","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/IAE.0b013e318030e999","article-title":"Prolongation of choroidal hypofluorescence following combined photodynamic therapy and intravitreal triamcinolone acetonide injection","volume":"27","author":"Luttrull","year":"2007","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305189-32","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/bjo.2007.122283","article-title":"Effect of intravitreal bevacizumab for polypoidal choroidal vasculopathy","volume":"92","author":"Gomi","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjo.2008.150029","article-title":"Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6\u2005month results","volume":"94","author":"Kokame","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2014-305189-34","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/IAE.0b013e3181f84fdf","article-title":"One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy","volume":"31","author":"Cheng","year":"2011","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2014-305189-35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/bjo.2011.204123","article-title":"Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy","volume":"96","author":"Wakabayashi","year":"2012","journal-title":"Br J Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2014-305189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:47:53Z","timestamp":1601110073000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2014-305189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,22]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,11,14]]},"published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1136\/bjophthalmol-2014-305189"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305189","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,22]]}}}